



SAFETY DATA SHEET

1. Identification

Product identifier Mirikizumab Injection

Other means of identification

Item Code 704020, 704021, PS3116, PS1437, 703641, 704051, 703642, 702486, 701643, 703093, 703091, 703088, CT9763, 703087, CT9762, 702421, 702485, 702484, PS8142, 702820, 701640, 701641, 701791, 702742, 702846, PS8012, 702291, 702550, 702170, PS8870, PS8011, 702442, VL7575, PS1408, 701325, 701792, PS7791, 701642, PS7792, 701640, PS7781, 702091, 702090, 701326, 701310, 701116, 701270, 701271, 701051, 701050, 701310, CT2084, 701804, CT2070, 701791, 700690, 701050, CT2068, 700692, 701271, CT2069, 700691, 701270, CT2071, 701793, 700801

Synonyms LY3074828 Injection

LY Number LY3074828

Recommended use Pharmaceutical

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company
Address Lilly Corporate Center
Indianapolis, IN 46285
United States

Telephone Phone: +1-317-276-2000

E-mail lilly_sds@lilly.com

Emergency phone number CHEMTREC: +1-800-424-9300

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.

Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Prevention Not available.

Response Not available.

Storage Not available.

Disposal Not available.

Hazard(s) not otherwise classified (HNOC) None known.

Supplemental information None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Mirikizumab		1884201-71-1	2 - 12.01

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations below reportable levels.

4. First-aid measures

Inhalation Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion	Get medical attention if symptoms occur.
Most important symptoms/effects, acute and delayed	This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to produce health effects through relevant routes of occupational exposures.
Indication of immediate medical attention and special treatment needed	Provide general supportive measures and treat symptomatically.
General information	If you feel unwell, seek medical advice (show the label where possible).

5. Fire-fighting measures

Suitable extinguishing media	Use fire-extinguishing media appropriate for surrounding materials.
Unsuitable extinguishing media	Not available.
Specific hazards arising from the chemical	Not applicable.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
General fire hazards	This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Avoid inhalation of mists or aerosols.
Methods and materials for containment and cleaning up	Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum. Wear appropriate protective equipment and clothing during clean-up.
Environmental precautions	Avoid release to the environment.

7. Handling and storage

Precautions for safe handling	Avoid contact with eyes, skin, and clothing.
Conditions for safe storage, including any incompatibilities	Keep container tightly closed in a dry and well-ventilated place.

8. Exposure controls/personal protection

Occupational exposure limits

Lilly (LEG) Components

	Type	Value
Mirikizumab (CAS 1884201-71-1)	TWA (12hrs)	90 µg/m ³
	TWA (8hrs)	130 µg/m ³

Biological limit values	No biological exposure limits noted for the ingredient(s).
Appropriate engineering controls	Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational exposure level (OEL).
Individual protection measures, such as personal protective equipment	
Eye/face protection	Safety glasses with side shields recommended. If splash potential or dusty operations, wear goggles/faceshield.
Skin protection	
Hand protection	Chemical resistant gloves.
Other	While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear impervious gloves and body covering (i.e. lab coat) to minimize skin contact.
Respiratory protection	If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an approved respirator with sufficient protection factor to control exposure below the OEL.
General hygiene considerations	Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

9. Physical and chemical properties

Appearance

Material name: Mirikizumab Injection

6572 Version #: 32 Revision date: 10-26-2023 Issue date: 09-14-2017

SDS US

2 / 5

Physical state	Liquid.
Form	Aqueous Solution
Color	Colorless
Odor	Not available.
Odor threshold	Not available.
pH	5.5
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or explosive limits	
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Soluble
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Explosive properties	Not explosive.
Oxidizing properties	The substance or mixture is not classified as oxidizing.

10. Stability and reactivity

Reactivity	Not water reactive.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	Hazardous polymerization does not occur.
Conditions to avoid	None under normal conditions.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Acute toxicity	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	
Respiratory sensitization	Due to inconclusive data the classification criteria are not met.
Skin sensitization	Due to inconclusive data the classification criteria are not met.
Germ cell mutagenicity	This substance is a monoclonal antibody. It does not possess mutagenic potential. Mutagenicity testing has not been conducted.
Carcinogenicity	Due to inconclusive data the classification criteria are not met.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity	Based on available data, the classification criteria are not met.
Specific target organ toxicity - single exposure	Based on available data, the classification criteria are not met.
Specific target organ toxicity - repeated exposure	Based on available data, the classification criteria are not met.
Aspiration hazard	Not applicable.
Further information	This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity	Not expected to be harmful to aquatic organisms.
Persistence and degradability	Not available.
Bioaccumulative potential	Not available.
Mobility in soil	Not available.
Other adverse effects	Not available.

13. Disposal considerations

Disposal instructions	Dispose in accordance with all applicable regulations.
------------------------------	--

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not available.
---	----------------

15. Regulatory information

US federal regulations	This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.
-------------------------------	--

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA) Not regulated.

US state regulations

California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins. For more information go to www.P65Warnings.ca.gov.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 09-14-2017

Revision date 10-26-2023

Version # 32

List of abbreviations

ACGIH: American Conference of Governmental Industrial Hygienists.
DOT: Department of Transportation (49 CFR 172.101)
IARC: International Agency for Research on Cancer.
IATA: International Air Transport Association.
IEG: Lilly Interim Exposure Guideline
IMDG: International Maritime Dangerous Goods Code
NTP: National Toxicology Program.
OSHA: Occupational Safety & Health Administration.
TWA: Time Weighted Average Value.

Disclaimer

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:
Eli Lilly and Company
Hazard Communication
+1-317-651-9533

Revision information

Product and Company Identification: Alternate Trade Names
Other information, including date of preparation or last revision: Disclaimer